CO HB1330

Creates supplemental state payments to qualified providers for office-administered oncology drugs who experienced reimbursement reductions in fiscal year 2017-18 due to federal rule changes published February 1, 2016.

Defines "qualified providers" as entities enrolled as of July 1, 2017, that provided office-administered drugs under Medicaid between July 1-December 31, 2017, and experienced documented reimbursement reductions for oncology-related drugs.

Requires the State Department to allocate $754,000 in general fund appropriations proportionate to each provider's documented reimbursement reduction, based on the difference between pre-implementation and post-implementation fee schedules.

Mandates supplemental payments be distributed no later than December 31, 2018, allows providers 30 days to request recalculation after notification, and permits recovery of payments if fraudulent claims are discovered.

Authorizes the statute to expire July 1, 2019, and includes an emergency safety clause.